IPO Trending
REMUSSME / NSEListed
Remus Pharmaceuticals

Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.

₹1,150 - ₹1,22961.53x sub
Listed Price₹1711.25
Listing Gain+39.24%

Subscription Status

61.53xTotal Demand
Updated 20 Oct 2026, 01:30 AM
QIB20.24x
Hot Bidding (High Profits)Offered: 73,700 sh
Nib172.60x
🔥 Blockbuster Sizzling Demand!Offered: 55,300 sh
Retail37.50x
🔥 Blockbuster Sizzling Demand!Offered: 1,29,000 sh
CategoryOfferedAppliedTimes
QIB73,70014,92,00020.24x
Nib55,30095,45,000172.6x
Retail1,29,00048,37,60037.5x

Segment Subscription Demand

Segment / CategoryDemand (Shares)Offered (Shares)Times Sub.
QIB183.379.0620.24x
Retail594.5415.8537.51x
Bidding status cross-verified with live IPO subscription numbers ↗BSE & NSE Bidding Portal Feed

About Remus Pharmaceuticals IPO Subscription Demand

Live subscription status and bidding analysis for Remus Pharmaceuticals (REMUS) IPO. The issue is subscribed 61.53x overall across Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII/HNI), and Retail Individual Investors (RII). Check real-time grey market demand on our GMP Tracker or review full issue details, lot size, and price band on the IPO Details Page.

Frequently Asked Questions